. Author manuscript; available in PMC: 2020 Jul 6.

Published in final edited form as: Ther Innov Regul Sci. 2015 Jul;49(4):493–502. doi: 10.1177/2168479015572370

Table 2.

Percentage of Participants who Gave the Correct Response to the Quantitative Knowledge Questions, by Information Type in Each Design

	Information Type
Quantitative Knowledge	No-information	Qualitative only	Numeric	Numeric + qualitative	Absolute difference + qualitative	Full
Benefit Design
Drug benefit	0.4	2.0	85.8^*^♦^{^}	87.5^*^♦^{^}	0.6	81.0^*^♦^{^}
Placebo benefit	0.0	0.0	75.7^*^♦^{^}	76.8^*^♦^{^}	0.0	73.9^*^♦^{^}
Comparative benefit	23.4	39.9^*	77.9^*^♦	76.0^*^♦	83.3^*^♦	82.0^*^♦
Drug risk	0.8	0.4	78.7^*^♦^{^}	77.6^*^♦^{^}	0.2	72.5^*^♦^{^}
Placebo risk	2.0	1.6	81.7^*^♦^{^}	80.6^*^♦^{^}	4.5	77.3^*^♦^{^}
Comparative risk	10.9	9.1	77.5^*^♦	73.1^*^♦^{^}	82.4^*^♦	79.4^*^♦
Risk Design
Drug benefit	3.2	17.8^*	89.3^*^♦^{^}^†	86.8^*^♦^{^}	3.1^♦	82.7^*^♦^{^}
Placebo benefit	0.0	0.0	81.6^*^♦^{^}	81.5^*^♦^{^}	1.0	80.1^*^♦^{^}
Comparative benefit	9.1	16.6	78.8^*^♦	78.4^*^♦	84.7^*^♦	83.5^*^♦
Drug risk	4.0	4.9	80.0^*^♦^{^}	78.0^*^♦^{^}	1.0	76.4^*^♦^{^}
Placebo risk	4.7	1.6	75.2^*^♦^{^}	74.1^*^♦^{^}	2.8	73.6^*^♦^{^}
Comparative risk	23.3	47.8^*	86.3^*^♦	85.3^*^♦	91.2^*^♦	87.2^*^♦

Note.

Significantly different from the no-information conditions.

^♦

Significantly different from the qualitative-only conditions

^{^}

Significantly different from the absolute difference + qualitative conditions.

^†

Significantly different from the full conditions. Significance was defined as p < .003.